Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-a antagonist treatment using a novel interleukin-8 reporter cell line

Research Project

Project/Area Number	15K09754
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Dermatology
Research Institution	Tohoku University
Principal Investigator	Kimura Yutaka 東北大学, 大学病院, 助教 (90375056)
Co-Investigator(Kenkyū-buntansha)	相場節也東北大学, 医学系研究科, 教授 (80159269)
Project Period (FY)	2015-10-21 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords	乾癬 / TNF-a阻害剤 / ルシフェラーゼアッセイ / インターロイキン-8 / 薬物動態 / THP-1 / 生物学的製剤 / TNF-a阻害薬 / ルシフェラーぜアッセイ
Outline of Final Research Achievements	There was a significant correlation between change in PASI and inhibitory rate of TNF-a induced IL-8 promoter activity. Therapeutic monitoring of patients with psoriasis during TNF-a antagonist therapy using IL-8 reporter cell line, THP-G8 can provide a useful tool to determine objectively the efficacy of the administered TNF-a antagonists. Furthermore, using IL-2 reporter cell line, several drugs including JAK inhibitors inhibited IL-2 promoter activity.

Report

(4 results)